novavax covid vaccine news

Novavax, FDA

Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again

Novavax (NVAX) shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results. The COVID-19 and flu vaccine maker said it expected full-year revenue of $650 million to $700 million, down from its ...

biopharma-reporter · 10h

FDA removes clinical hold on Novavax’s COVID-19-influenza combo vaccine

The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.

KSL · 18h

FDA lifts clinical hold on Novavax's combo COVID-flu shot

The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after identifying a safety concern.

MarketWatch · 1d

Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.

Investopedia · 1d

Novavax Gets FDA Approval To Resume Testing Two Vaccines After Clinical Hold

Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

Hosted on MSN4h

Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales

(Reuters) -Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine ...

Yahoo Finance2h

FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

AOL5h

Novavax: Stock plunges after quarterly earnings, but sees hope in licensing deals

Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, ...

emjreviews.com3h

FDA Lifts Hold on COVID-Flu Combo Vaccine Trial

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

Becker's Hospital Review3h

FDA lifts clinical hold on combined COVID-19-influenza vaccine trials

Novavax received clearance from the FDA to move forward with phase 3 clinical trials for its COVID-19-influenza combination (CIC ... confirming that the event was not related to the ...

Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls

Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...

Daily15h

USFDA removes clinical hold on Novavax COVID Influenza combination, stand alone Influenza Phase 3 trial

Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has announced that ...

13d

Moderna, Pfizer or Novavax? How the three Covid-19 vaccines differ according to Yale Medicine

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

FiercePharma6d

Novavax coughs up $123.8M to settle COVID vaccine supply dispute with UK

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Novavax, FDA

Related topics